Generic business has plummeted first four months of this calendar year and hence the downgrades. Analysts just want to see a turn around in the generic business unit prior to shifting their forecasts. Analysts are lag indicators not leading indicators.
News: MYX Mayne Pharma Expects Q4 To Be Stronger Driven By Rebound In Generic Products, page-12
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.64 |
Change
-0.070(1.49%) |
Mkt cap ! $394.7M | |||
| Open | High | Low | Value | Volume |
| $4.68 | $4.77 | $4.62 | $619.8K | 132.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 348 | $4.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.66 | 620 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |